Glenmark Pharmaceuticals Dirección
Dirección controles de criterios 1/4
El CEO de Glenmark Pharmaceuticals' es Glenn Saldanha , nombrado en Jan 2001, tiene una permanencia de 23.25 años. compensación anual total es ₹161.85M, compuesta por 80.2% salario y 19.8% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.35% de las acciones de la empresa, por valor de ₹1.02B. La antigüedad media del equipo directivo y de la junta directiva es de 1.6 años y 12.3 años, respectivamente.
Información clave
Glenn Saldanha
Chief Executive Officer (CEO)
₹161.9m
Compensación total
| Porcentaje del salario del CEO | 80.2% |
| Permanencia del CEO | 23.6yrs |
| Participación del CEO | 0.4% |
| Permanencia media de la dirección | 1.8yrs |
| Promedio de permanencia en la Junta Directiva | 12.6yrs |
Actualizaciones recientes de la dirección
Shareholders Will Probably Hold Off On Increasing Glenmark Pharmaceuticals Limited's (NSE:GLENMARK) CEO Compensation For The Time Being
Sep 23
Shareholders Will Probably Hold Off On Increasing Glenmark Pharmaceuticals Limited's (NSE:GLENMARK) CEO Compensation For The Time Being
Sep 21Recent updates
Calculating The Fair Value Of Glenmark Pharmaceuticals Limited (NSE:GLENMARK)
Aug 06Does Glenmark Pharmaceuticals (NSE:GLENMARK) Have A Healthy Balance Sheet?
Jun 16Is Glenmark Pharmaceuticals Limited (NSE:GLENMARK) Expensive For A Reason? A Look At Its Intrinsic Value
May 08Glenmark Pharmaceuticals (NSE:GLENMARK) Takes On Some Risk With Its Use Of Debt
Mar 09Is Glenmark Pharmaceuticals (NSE:GLENMARK) Using Too Much Debt?
Dec 07Shareholders Will Probably Hold Off On Increasing Glenmark Pharmaceuticals Limited's (NSE:GLENMARK) CEO Compensation For The Time Being
Sep 23Glenmark Pharmaceuticals (NSE:GLENMARK) Will Pay A Dividend Of ₹2.50
Sep 17Glenmark Pharmaceuticals (NSE:GLENMARK) Has Announced A Dividend Of ₹2.50
Aug 30A Look At The Intrinsic Value Of Glenmark Pharmaceuticals Limited (NSE:GLENMARK)
Aug 28We Think Glenmark Pharmaceuticals (NSE:GLENMARK) Is Taking Some Risk With Its Debt
Jul 03A Look At The Fair Value Of Glenmark Pharmaceuticals Limited (NSE:GLENMARK)
May 28Glenmark Pharmaceuticals (NSE:GLENMARK) Has A Somewhat Strained Balance Sheet
Mar 22Estimating The Fair Value Of Glenmark Pharmaceuticals Limited (NSE:GLENMARK)
Feb 14An Intrinsic Calculation For Glenmark Pharmaceuticals Limited (NSE:GLENMARK) Suggests It's 37% Undervalued
Oct 12Shareholders Will Probably Hold Off On Increasing Glenmark Pharmaceuticals Limited's (NSE:GLENMARK) CEO Compensation For The Time Being
Sep 21Glenmark Pharmaceuticals (NSE:GLENMARK) Has Announced A Dividend Of ₹2.50
Aug 29We Think Glenmark Pharmaceuticals (NSE:GLENMARK) Can Stay On Top Of Its Debt
Jun 20There May Be Reason For Hope In Glenmark Pharmaceuticals' (NSE:GLENMARK) Disappointing Earnings
Jun 04An Intrinsic Calculation For Glenmark Pharmaceuticals Limited (NSE:GLENMARK) Suggests It's 27% Undervalued
May 05If You Like EPS Growth Then Check Out Glenmark Pharmaceuticals (NSE:GLENMARK) Before It's Too Late
Mar 25A Look At The Intrinsic Value Of Glenmark Pharmaceuticals Limited (NSE:GLENMARK)
Jan 18We Think Glenmark Pharmaceuticals (NSE:GLENMARK) Can Stay On Top Of Its Debt
Dec 13Análisis de compensación del CEO
| Fecha | Compensación total | Salario | Ingresos de la empresa |
|---|---|---|---|
| Mar 31 2024 | n/a | n/a | -₹19b |
| Dec 31 2023 | n/a | n/a | -₹8b |
| Sep 30 2023 | n/a | n/a | -₹1b |
| Jun 30 2023 | n/a | n/a | ₹3b |
| Mar 31 2023 | ₹162m | ₹130m | ₹3b |
| Dec 31 2022 | n/a | n/a | ₹9b |
| Sep 30 2022 | n/a | n/a | ₹8b |
| Jun 30 2022 | n/a | n/a | ₹8b |
| Mar 31 2022 | ₹158m | ₹130m | ₹9b |
| Dec 31 2021 | n/a | n/a | ₹10b |
| Sep 30 2021 | n/a | n/a | ₹10b |
| Jun 30 2021 | n/a | n/a | ₹10b |
| Mar 31 2021 | ₹139m | ₹110m | ₹10b |
| Dec 31 2020 | n/a | n/a | ₹10b |
| Sep 30 2020 | n/a | n/a | ₹9b |
| Jun 30 2020 | n/a | n/a | ₹9b |
| Mar 31 2020 | ₹122m | ₹91m | ₹8b |
| Dec 31 2019 | n/a | n/a | ₹7b |
| Sep 30 2019 | n/a | n/a | ₹6b |
| Jun 30 2019 | n/a | n/a | ₹8b |
| Mar 31 2019 | ₹157m | ₹131m | ₹9b |
| Dec 31 2018 | n/a | n/a | ₹9b |
| Sep 30 2018 | n/a | n/a | ₹9b |
| Jun 30 2018 | n/a | n/a | ₹7b |
| Mar 31 2018 | ₹162m | ₹134m | ₹8b |
Compensación vs. Mercado: La compensación total de Glenn($USD1.94M) está por encima de la media de empresas de tamaño similar en el mercado Indian ($USD562.53K).
Compensación vs. Ingresos: La compensación de Glenn ha aumentado mientras la empresa no es rentable.
CEO
Glenn Saldanha (54 yo)
23.6yrs
Permanencia
₹161,850,000
Compensación
Mr. Glenn Mario Saldanha has been the Managing Director and Chief Executive Officer of Glenmark Pharmaceuticals Limited since 2000. Mr. Saldanha serves as Chairman at Ichnos Sciences Inc. Mr. Saldanha serv...
Equipo directivo
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| Chairman | 23.6yrs | ₹161.85m | 0.35% ₹ 1.4b | |
| Global CFO & Executive Director | 6.8yrs | ₹102.47m | sin datos | |
| Executive Director of Corporate Services & Executive Director | no data | ₹45.86m | 0.27% ₹ 1.1b | |
| Company Secretary & Compliance Officer | 7.5yrs | ₹5.71m | sin datos | |
| President and Chief Human Resources Officer | 2.6yrs | sin datos | sin datos | |
| President & Head of Global Pharmaceutical Development | 1.9yrs | sin datos | sin datos | |
| President & Chief Quality Officer | less than a year | sin datos | sin datos | |
| President & Global Head of Formulation Operations | less than a year | sin datos | sin datos | |
| President & Business Head of India Formulations | less than a year | sin datos | sin datos | |
| President and Business Head of Europe & Emerging Markets | 1.6yrs | sin datos | sin datos | |
| President & Business Head of North America | less than a year | sin datos | sin datos | |
| Investor Relations Officer | no data | sin datos | sin datos |
1.8yrs
Permanencia media
55yo
Promedio de edad
Equipo directivo experimentado: El equipo directivo de GLENMARK no se considera experimentado ( 1.6 años antigüedad media), lo que sugiere un nuevo equipo.
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| Chairman | 25.8yrs | ₹161.85m | 0.35% ₹ 1.4b | |
| Global CFO & Executive Director | 6.3yrs | ₹102.47m | sin datos | |
| Executive Director of Corporate Services & Executive Director | 24.8yrs | ₹45.86m | 0.27% ₹ 1.1b | |
| Non Executive Director | 19yrs | ₹400.00k | 0.39% ₹ 1.6b | |
| Non-Executive Independent Director | 22.3yrs | ₹1.70m | 0.039% ₹ 154.8m | |
| Independent Non-Executive Director | 1.5yrs | ₹100.00k | sin datos | |
| Independent Non-Executive Director | 4yrs | ₹900.00k | sin datos | |
| Independent Non-Executive Director | 5.3yrs | ₹1.30m | sin datos |
12.6yrs
Permanencia media
61yo
Promedio de edad
Junta con experiencia: Los miembros de la junta directiva de GLENMARK son experimentados ( 12.3 años antigüedad media).